LHT-7

LHT-7 (heparin-taurocholate conjugate) is a low molecular weight heparin derivative developed as a multi-targeting anti-angiogenic agent for the treatment of solid tumors, including breast cancer, pancreatic cancer, and glioblastoma. It is synthesized by covalently conjugating low molecular weight heparin with taurocholic acid (a bile acid), which significantly reduces its anticoagulant activity while enhancing its binding affinity to multiple angiogenic growth factors. LHT-7 exerts its therapeutic effects by binding to and blocking key pro-angiogenic growth factors, including vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), and platelet-derived growth factor B (PDGF-B), thereby inhibiting the phosphorylation of their respective receptors (VEGFR2, FGFR1, and PDGFR-beta) and suppressing tumor angiogenesis and metastasis.

Other names

heparin-taurocholate conjugateheparin-taurocholic acid conjugatelow molecular weight heparin-taurocholate conjugatelow molecular weight heparin-taurocholic acid conjugate